<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365161">
  <stage>Registered</stage>
  <submitdate>17/10/2013</submitdate>
  <approvaldate>10/12/2013</approvaldate>
  <actrnumber>ACTRN12613001351707</actrnumber>
  <trial_identification>
    <studytitle>Effects of low dose everolimus and/or BEZ235 on vaccine response in the elderly</studytitle>
    <scientifictitle>A multicenter, blinded, placebo-controlled study to investigate the effects of everolimus and/or BEZ235 on the immune response to vaccination in the elderly.</scientifictitle>
    <utrn>U1111-1149-3106</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Immune response to vaccination</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Everolimus, BEZ235 and corresponding placebo tablets and capsules will be dosed on a once-daily basis. Subjects will receive placebo, 0.1 mg or 0.5 mg everolimus daily, 10 mg BEZ235 daily, or a combination of 0.1 mg everolimus and 10 mg BEZ235 daily for 6 weeks.

Subjects will use a patient diary to record how many tablets are taken on each day. Subjects are required to bring back tablets or empty boxes to the clinic for drug accountability.

Standard flu vaccine (FluVax) will be given at day 56. Fluvax dose is 0.5ml and mode of delivery is intramuscular or deep subcutaneous injection.</interventions>
    <comparator>*Everolimus 0.1 mg (1 tablet) daily or matched placebo (1 tablet)
*Everolimus 0.5 mg (2 x 0.25mg tablets) daily or matched placebo (2 tablets)
*BEZ235 10 mg (2 x 5mg tablet) daily or matched placebo (2 tablet)
*Everolimus 0.1 mg daily and BEZ235 10 mg (3 tablets) daily or matched placebo (3 tablets)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the efficacy of low dose everolimus and/or BEZ235 in enhancing the immune response to vaccination in the elderly as determined by the change in hemagglutination inhibition (HI) geometric mean titers (GMTs) 4-weeks post influenza vaccination.

Assessed using serum assays.</outcome>
      <timepoint>4-weeks post influenza vaccination</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To assess the safety and tolerability of low dose everolimus and/or BEZ235 in the elderly. Assessed via adverse event reporting and safety labs (chemistry and haematology lab tests).

Known adverse events for both BEZ and everolimus include stomatitis, nausea, vomiting and diarrhoea. </outcome>
      <timepoint>Throughout trial participation (12 months)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the efficacy of low dose everolimus and/or BEZ235 in enhancing the immune response to vaccination in the elderly as determined by rates of seroconversion and seroprotection 4-weeks post influenza vaccination

Assessed using serum assays.</outcome>
      <timepoint> 4-weeks post influenza vaccination</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the efficacy of low dose everolimus and/or BEZ235 in enhancing the immune response to vaccination in the elderly as determined by the change in HI GMTs 1-week post influenza vaccination.

Assessed using serum assays.</outcome>
      <timepoint>1-week post influenza vaccination</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the PK of low dose everolimus and/or BEZ235 in the elderly.

Assessed using plasma assays and whole blood assays.</outcome>
      <timepoint>1h post blood withdrawal on day 28.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Informed Consent obtained
&gt;= 65 yo, male and female
&gt;=40kg</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Subjects with underlying unstable medical conditions. </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>False</masking1>
    <masking2>False</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>17/12/2013</anticipatedstartdate>
    <actualstartdate>18/12/2013</actualstartdate>
    <anticipatedenddate>5/05/2014</anticipatedenddate>
    <actualenddate>4/04/2014</actualenddate>
    <samplesize>240</samplesize>
    <actualsamplesize>240</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>27/04/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Institutes for BioMedical Research</primarysponsorname>
    <primarysponsoraddress>220 Massachusetts Avenue Cambridge, MA 02139 USA </primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis International AG</fundingname>
      <fundingaddress>Novartis International AG
CH-4002 Basel
Switzerland</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A proof of concept study to determine if inhibiting a protein with study drugs everolimus and/or BEZ235 enhances the immune response to vaccination in the elderly at doses that are safe and tolerable.</summary>
    <trialwebsite />
    <publication>The trial has not yet been cited to date. There is, however, a full Clinical Study Report available and distributed to all participating sites.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committees</ethicname>
      <ethicaddress>Ministry of Health
No 1 The Terrace
PO Box 5013
Wellington 6145</ethicaddress>
      <ethicapprovaldate>4/12/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>17/10/2013</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dean Quinn</name>
      <address>P3 Research Limited
First Floor 121 Adelaide Road
Newtown
Wellington 6021, NEW ZEALAND</address>
      <phone>+64 4 801 0002</phone>
      <fax />
      <email>dean@p3research.co.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Jaybee David</name>
      <address>Pharmaceutical Solutions Limited, Level 1, The Levy Building, 20 Customs Street East, Auckland CBD 1010</address>
      <phone>+64 9 379 8205</phone>
      <fax />
      <email>jaybeed@pharmasols.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Joan Mannick</name>
      <address>Novartis Institutes for BioMedical Research, Inc.
Clinical Science and Innovation
220 Massachusetts Avenue, 346J
Cambridge, MA 02139 USA</address>
      <phone>+1 617 871 5659</phone>
      <fax />
      <email>joan.mannick@novartis.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Jaybee David</name>
      <address>Pharmaceutical Solutions Limited, Level 1, The Levy Building, 20 Customs Street East, Auckland CBD 1010</address>
      <phone>+64 9 379 8205</phone>
      <fax />
      <email>jaybeed@pharmasols.com</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>